search
Back to results

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

Primary Purpose

Edentulous Alveolar Ridge

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Gintuit
Bio-Gide
Sponsored by
Organogenesis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Edentulous Alveolar Ridge

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is at least 18 years of age but no more than 75 years of age.
  • Subject has a posterior (molar or premolar) socket created by atraumatic extraction with a post extraction socket of a minimum of 5 mm in both the mesial-distal (M-D) and buccal-lingual (B-L) dimensions that requires bone grafting.
  • Subject has sufficient buccal bone plate at the site of the planned tooth extraction (ie, the residual socket should be of a form that would retain bone graft material), as judged by the Principal Investigator.
  • Females of childbearing potential must have a documented negative urine pregnancy test. All subjects must agree to use acceptable methods of contraception for the duration of the study.
  • Subjects must have read, understood, and signed an institutional review board (IRB)-approved Informed Consent Form (ICF).
  • Subjects must be able and willing to comply with protocol requirements.

Exclusion Criteria:

  • Subject with any systemic conditions that could compromise wound healing and preclude periodontal surgery (ie, bleeding disorder, cancer, except localized basal cell or squamous cell cancer of the skin with no metastasis; human immunodeficiency virus; or bone metabolic diseases [ie, osteoporosis or Paget's disease]).
  • Subject who is currently receiving, anticipates receiving or has received within 30 days prior to Day 0: inhaled or systemic corticosteroids (ie, oral, IV), immunosuppressive agents or radiation therapy, and/or chemotherapy, which could compromise wound healing and preclude periodontal surgery.
  • Subject who has had oral/periodontal surgery within 30 days prior to Day 0 or anticipates having oral/periodontal surgery within 30 days after Day 0.
  • Subject with acute mucosal infection, including suppuration or induration in the area of intended surgery.
  • Subject, who in the opinion of the Principal Investigator, will require a sinus lift procedure to place dental implants in the surgical area.
  • Subject without at least 1 tooth adjacent to the area to be treated.
  • Subject has a history of alcohol or substance abuse within the previous 12 months of Screening that could interfere with study compliance or protocol requirements.
  • Subject who has used any tobacco product within 6 months of Screening.
  • Subject with known hypersensitivity to porcine or bovine collagen, gentamicin or surfactants.
  • Subject who has received an investigational drug, device, or biological/bioactive treatment within 30 days prior to Day 0 (medical or dental).
  • Subject who was previously treated with Gintuit, or any other cell therapy at the target treatment site or immediately adjacent teeth.
  • Female subject that is lactating.
  • Subject, who in the opinion of the Principal Investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

Sites / Locations

  • Kevin G. Murphy and Associates, P.A.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Gintuit

Bio-Gide

Arm Description

Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.

Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.

Outcomes

Primary Outcome Measures

Number of participants with adverse events

Secondary Outcome Measures

Optimal product configuration (ie, single, folded, or z-folded)
Subjective assessment based on the results of the analyses of safety, efficacy and product handling (from surgeon input) data
Number of participants reporting loose graft material
Percentage of participants with soft tissue closure
Measurements of bone height
Gintuit product handling
Rated as excellent, very good, good, adequate, poor
Number of participants with visible loss of graft material
Percentage of participants with convex, normal and concave soft tissue contour
Measurement of soft tissue ridge contour
Measurement of soft tissue thickness
Percentage of participants with color and texture match
Percentage of participants with a clinically significant physical reduction of crestal ridge height
Clinically significant defined as > 2 mm loss at the crest of the ridge at the graft site compared to Day 0
Measurements of soft tissue ridge height
Measurements of ridge width of hard tissue
Bone quality
Regularity and density of the cortical and trabecular bone using the system described by Norton and Gamble (Quality Levels 1, 2/3, 4 and 4 (failure zone))
Percentage of participants with acceptable implant stability
Acceptable implant stability defined as an implant stability quotient of >/= 55

Full Information

First Posted
August 13, 2013
Last Updated
September 23, 2015
Sponsor
Organogenesis
search

1. Study Identification

Unique Protocol Identification Number
NCT01929954
Brief Title
Safety Study of Gintuit™ in Subjects Requiring Socket Grafting
Official Title
Phase 1/2, Randomized, Controlled Assessment of the Safety Of Gintuit™ Versus Bio-Gide® in Subjects Requiring Socket Grafting
Study Type
Interventional

2. Study Status

Record Verification Date
September 2015
Overall Recruitment Status
Terminated
Why Stopped
Changes in corporate business environment
Study Start Date
July 2013 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Organogenesis

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, randomized, controlled, parallel group Phase 1/2 assessment of the safety of GINTUIT versus Bio-Gide in subjects who have a posterior tooth requiring extraction. The incidence and severity of adverse events will be summarized by group (GINTUIT and Bio-Gide).
Detailed Description
This study will evaluate the safety of GINTUIT as compared with Bio-Gide in subjects who have a posterior tooth requiring extraction. The use of GINTUIT in this investigational clinical indication may eliminate/reduce the need for aggressive flap advancement with its concomitant morbidity, while, at the same time, obtaining stable closure over a grafted socket. It is anticipated that GINTUIT will facilitate tissue granulation, followed by tissue coverage with site appropriate tissue (ie, keratinized tissue) that is needed for long term stability of the final restoration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Edentulous Alveolar Ridge

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Gintuit
Arm Type
Experimental
Arm Description
Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.
Arm Title
Bio-Gide
Arm Type
Active Comparator
Arm Description
Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.
Intervention Type
Biological
Intervention Name(s)
Gintuit
Intervention Description
One time placement of Gintuit over socket graft.
Intervention Type
Device
Intervention Name(s)
Bio-Gide
Intervention Description
One time placement of Bio-Gide over socket graft.
Primary Outcome Measure Information:
Title
Number of participants with adverse events
Time Frame
up to 12 months post treatment
Secondary Outcome Measure Information:
Title
Optimal product configuration (ie, single, folded, or z-folded)
Description
Subjective assessment based on the results of the analyses of safety, efficacy and product handling (from surgeon input) data
Time Frame
One month after placement of Gintuit in the last subject in the last successful cohort
Title
Number of participants reporting loose graft material
Time Frame
Up to 21 days post treatment
Title
Percentage of participants with soft tissue closure
Time Frame
Up to 4 weeks post treatment
Title
Measurements of bone height
Time Frame
Up to 6 months post treatment
Title
Gintuit product handling
Description
Rated as excellent, very good, good, adequate, poor
Time Frame
At Day 0
Title
Number of participants with visible loss of graft material
Time Frame
Up to 3 months post treatment
Title
Percentage of participants with convex, normal and concave soft tissue contour
Time Frame
Up to 6 months post treatment
Title
Measurement of soft tissue ridge contour
Time Frame
Up to 6 months post treatment
Title
Measurement of soft tissue thickness
Time Frame
Up to 6 months post treatment
Title
Percentage of participants with color and texture match
Time Frame
Up to 6 months post treatment
Title
Percentage of participants with a clinically significant physical reduction of crestal ridge height
Description
Clinically significant defined as > 2 mm loss at the crest of the ridge at the graft site compared to Day 0
Time Frame
Up to 6 months post treatment
Title
Measurements of soft tissue ridge height
Time Frame
Up to 6 months post treatment
Title
Measurements of ridge width of hard tissue
Time Frame
Up to 6 months post treatment
Title
Bone quality
Description
Regularity and density of the cortical and trabecular bone using the system described by Norton and Gamble (Quality Levels 1, 2/3, 4 and 4 (failure zone))
Time Frame
Up to 6 months post treatment
Title
Percentage of participants with acceptable implant stability
Description
Acceptable implant stability defined as an implant stability quotient of >/= 55
Time Frame
Up to 12 months post treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is at least 18 years of age but no more than 75 years of age. Subject has a posterior (molar or premolar) socket created by atraumatic extraction with a post extraction socket of a minimum of 5 mm in both the mesial-distal (M-D) and buccal-lingual (B-L) dimensions that requires bone grafting. Subject has sufficient buccal bone plate at the site of the planned tooth extraction (ie, the residual socket should be of a form that would retain bone graft material), as judged by the Principal Investigator. Females of childbearing potential must have a documented negative urine pregnancy test. All subjects must agree to use acceptable methods of contraception for the duration of the study. Subjects must have read, understood, and signed an institutional review board (IRB)-approved Informed Consent Form (ICF). Subjects must be able and willing to comply with protocol requirements. Exclusion Criteria: Subject with any systemic conditions that could compromise wound healing and preclude periodontal surgery (ie, bleeding disorder, cancer, except localized basal cell or squamous cell cancer of the skin with no metastasis; human immunodeficiency virus; or bone metabolic diseases [ie, osteoporosis or Paget's disease]). Subject who is currently receiving, anticipates receiving or has received within 30 days prior to Day 0: inhaled or systemic corticosteroids (ie, oral, IV), immunosuppressive agents or radiation therapy, and/or chemotherapy, which could compromise wound healing and preclude periodontal surgery. Subject who has had oral/periodontal surgery within 30 days prior to Day 0 or anticipates having oral/periodontal surgery within 30 days after Day 0. Subject with acute mucosal infection, including suppuration or induration in the area of intended surgery. Subject, who in the opinion of the Principal Investigator, will require a sinus lift procedure to place dental implants in the surgical area. Subject without at least 1 tooth adjacent to the area to be treated. Subject has a history of alcohol or substance abuse within the previous 12 months of Screening that could interfere with study compliance or protocol requirements. Subject who has used any tobacco product within 6 months of Screening. Subject with known hypersensitivity to porcine or bovine collagen, gentamicin or surfactants. Subject who has received an investigational drug, device, or biological/bioactive treatment within 30 days prior to Day 0 (medical or dental). Subject who was previously treated with Gintuit, or any other cell therapy at the target treatment site or immediately adjacent teeth. Female subject that is lactating. Subject, who in the opinion of the Principal Investigator, for any reason other than those listed above, will not be able to complete the study per protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin G. Murphy, DDS, MS
Organizational Affiliation
Kevin G. Murphy Associates, P.A.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kevin G. Murphy and Associates, P.A.
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21209
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

We'll reach out to this number within 24 hrs